The size of the European Monoclonal Antibodies Market was worth USD 9.63 Billion in 2020 and estimated to be growing at a CAGR of 5.32%, to reach USD 16.37 Billion by 2025. Europe countries monoclonal antibody development play a key role in cancer diagnosis & treatment. It can new opportunities to Pharmaceutical, biotechnology & bioinformatics companies to innovate new drugs, equipment through monoclonal antibodies.
Every year more than 20000 patients are dying in the European countries due to bacterial infections with serious resistant. Scientist innovates the new antibacterial treatments to reduce the high resistant of bacterial infections and save a life. AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center are collaborating to develop the novel antibody therapeutics to prevent coronavirus.
MAb`s are antibodies produced by a single clone of cells consisting of identical antibody molecules. Monoclonal Antibodies have various diagnostic and therapeutic applications, especially in cancer. Apart from these mAb`s are also useful in protein purification. Growth in sales of currently approved monoclonal antibody products, along with 300 monoclonal antibody products currently in development, will show significant growth in sales of mAb products in the coming five years.
European laboratories are linked up with academic Institutes for the production of Monoclonal antibodies. Europe has a well-developed infrastructure of laboratories which is estimated to propel the demand of the market to the extent. Increasing incidences of various health disorders are enhancing the growth rate of this market. Use of different methodology, techniques for improvement in antibodies production such as recombinant technology. The researcher uses this Monoclonal antibody as research or diagnostic tools.
MARKET DYNAMICS
Europe Monoclonal Antibodies market is driven by increasing research and development activities, owing to the introduction of advanced methods for mAb production. Major pharmaceutical companies are building their own product pipeline for the development of new molecules. Growing consumer awareness about various benefits and applications of mAb is also a major driving factor for the market growth.
However huge cost and time associated with the identification and development, and stringent regulatory framework are the key restraining factors for the market growth.
RECENT MARKET DEVELOPMENTS
OSE Immunotherapeutic announced a new collaboration with startup MAbSilico. Artificial intelligence use for therapeutic antibody drug development as solutions. Technique help to reduce the risk of failure & accelerate the pre-clinical process. OSE provide internal data to MAbSilico for their drug development & deliver a faster result in research.
Sanofi & Regeneron Pharmaceutical Inc. has started the clinical trials to treat coronavirus. The clinical trial is based on their rheumatoid arthritis drug Kevzara as a treatment. Kevzara is an infection-fighting protein it is known as Monoclonal antibody.
This research report has been segmented & sub-segmented into the following categories:
Regionally, Europe is the second-largest market for monoclonal antibodies accounting for a major share. Within Europe, Germany is the largest market for monoclonal antibodies followed by the United Kingdom.
Key market participants in the Europe Monoclonal Antibodies Market profiled in this report are GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, Seattle Genetics, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd. and Biogen Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Source
5.1.1 Murine
5.1.2 Chimeric
5.1.3 Humanized
5.1.4 Human
5.2 By Indication
5.2.1 Cancer
5.2.1.1 Blood Cancer
5.2.1.2 Breast Cancer
5.2.1.3 Colorectal Cancer
5.2.1.4 Lung Cancer
5.2.1.5 Pancreatic Cancer
5.2.1.6 Others
5.2.2 Autoimmune Diseases
5.2.3 Infectious Diseases
5.2.4 Cardiovascular Diseases
5.2.5 CNS Disorders
5.2.6 Others (Inflammatory, Microbial Diseases, & Other)
5.3 End User
5.3.1 Hospitals/Clinics
5.3.2 Research Institute
5.3.3 Diagnostic Laboratories
5.4 Application
5.4.1 Medical
5.4.2 Experimental
5.4.2.1 Western Blot
5.4.2.2 ELISA
5.4.2.3 Radioimmune Assays
5.4.2.4 Immunofluorescence
5.4.2.5 Other (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)
6. Geographical Analysis
6.1 Europe
6.1.1 Introduction
6.1.2 U.K
6.1.3 Spain
6.1.4 Germany
6.1.5 Italy
6.1.6 France
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
7.5 Key Trends in Monoclonal Antibodies Development
7.5.1 Targeted Therapies
7.6 Promising Monoclonal Antibodies in Pipeline
7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Monoclonal Antibodies
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 GlaxoSmithKline plc (U.K.)
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.2 Novartis AG (Switzerland)
9.3 Pfizer Inc. (U.S.)
9.4 Thermo Fisher Scientific Inc. (U.S.)
9.5 Eli Lilly and Company (U.S.)
9.6 AstraZeneca (U.K.)
9.7 Bristol-Myers Squibb (U.S.)
9.8 F. Hoffmann-La Roche Ltd. (Switzerland)
9.9 Ablynx NV (Belgium)
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Market Outlook & Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
Download Sample
